September 9, 2024 02:42 PM EDT

GSK says long-acting asthma hopeful significantly cut attacks

Nicole DeFeudis

Editor

GSK said Monday that its projected asthma blockbuster depemokimab reduced asthma attacks by 54% in two large Phase 3 trials, but missed some secondary endpoints …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK says long-acting asthma hopeful significantly cut attacks

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Boehringer plans NDA filing for pulmonary fibrosis drug following Phase 3 data

FDA tells oncology companies how to run multi-regional cancer trials with a US approval in mind

Breaking down silos with a new quantitative approach to drug development

GSK says long-act­ing asth­ma hope­ful sig­nif­i­cant­ly cut at­tacks

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

GSK says long-acting asthma hopeful significantly cut attacks